Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript
Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript
Pacira (PCRX) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.78 per share a year ago.
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
